Liecba Vypadávanie vlasov

Hair loss liečba v Európe

Hair loss — medically referred to as alopecia — affects a significant proportion of the European population. Androgenetic alopecia, commonly known as male or female pattern baldness, is the most prevalent form. It is estimated that approximately 50% of men experience noticeable hair loss by the age of 50, and female pattern hair loss is also more common than widely recognised, affecting an estimated 40% of women by the age of 70.

Androgenetic alopecia is driven primarily by genetic predisposition and the action of dihydrotestosterone (DHT), a potent androgen derived from testosterone via the enzyme 5-alpha reductase. DHT causes miniaturisation of hair follicles, leading to progressively finer and shorter hair until follicles are no longer productive. The pattern of loss differs between males and females: men typically experience recession at the temples and crown, while women more commonly experience diffuse thinning over the top of the scalp.

The psychological impact of hair loss should not be underestimated. Research published in peer-reviewed journals has consistently documented associations between hair loss and reduced self-esteem, anxiety, and in some cases clinical depression. The availability of effective pharmacological treatments has improved significantly over recent decades, offering meaningful benefit for many patients when treatment is initiated early.

Prescription medications for hair loss work through different mechanisms. Finasteride and dutasteride reduce DHT levels systemically. Minoxidil, available in both topical and oral formulations, acts as a vasodilator that prolongs the growth phase of hair follicles. All treatment decisions should be made by a qualified, independent doctor based on thorough clinical assessment.

Dostupné liečby

The following medications are available for hair loss treatment through EU-registered doctors. This comparison is provided for informational purposes only. A doctor will assess which medication, if any, is appropriate for your individual situation.

Key distinctions:

• Finasteride: The first-line oral treatment for male androgenetic alopecia. Clinical studies show it can halt progression and promote regrowth in the majority of men. Not appropriate for women of childbearing potential.
• Minoxidil: Available in topical and, increasingly, low-dose oral formulations. Approved for use in both men and women. Effective as monotherapy or in combination with finasteride.
• Dutasteride: Achieves higher DHT suppression than finasteride due to dual enzyme inhibition. Some clinical evidence supports greater efficacy, but it carries an off-label status for hair loss in most EU jurisdictions. A doctor will advise whether it is appropriate for you.

Ako získať liečba online

Prescrivia pôsobí ako technologický sprostredkovateľ: nepredpisujeme lieky, nezamestnávame lekárov ani nepredávame lieky. Naša platforma spája pacientov s nezávislými lekármi registrovanými v EÚ, ktorí môžu vykonávať dôverné online zdravotné posúdenia.

Postup je nasledovný:

1. Vyplňte zdravotný dotazník — Answer a structured set of medical questions covering the pattern and duration of your hair loss, family history, current medications, and relevant medical history. Photos may be requested to support the clinical assessment.

2. Independent doctor review — An independent EU-registered doctor reviews your assessment. If a hair loss medication is clinically appropriate, the doctor may issue a prescription. If it is not appropriate for your circumstances, the doctor will explain the reasoning.

3. Predpis a vybavenie — If a prescription is issued, it is passed to a licensed EU pharmacy partner. The pharmacy dispenses the medication and arranges delivery directly to your address.

Dôležité: Prescrivia nezaručuje, že bude predpis vystavený. Všetky rozhodnutia o predpisovaní vykonávajú nezávisle kvalifikovaní odborní lekári na základe Vašich individuálnych klinických okolností. Prescription hair loss medications require a valid prescription from a licensed doctor.

Ako sa porovnávame

Note: Sudden or patchy hair loss, hair loss accompanied by scalp changes, or loss that may be secondary to an underlying medical condition (such as thyroid disease or nutritional deficiency) warrants in-person investigation before treatment. Prescrivia’s platform is designed for adults whose hair loss pattern is consistent with androgenetic alopecia suitable for remote assessment.

Zdroje

Lekárske informácie na tejto stránke vychádzajú z nasledujúcich zdrojov:

• European Medicines Agency (EMA). Propecia (finasteride) — Summary of Product Characteristics. Available at: ema.europa.eu
• Blumeyer A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and men. JDDG. 2011;9(S6).
• World Health Organization (WHO). Dermatological conditions — regional data. who.int

Tento obsah je pravidelne prehodnocovaný s ohľadom na aktualizované klinické usmernenia. Je poskytovaný len na informačné účely a nepredstavuje lekárske poradenstvo. Vždy sa poraďte s kvalifikovaným zdravotníckym pracovníkom o rade týkajúcej sa Vašich individuálnych zdravotných okolností.